Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

HSCI / HK Connect May 2026 Review Forecast

HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning

HSCI / HK Connect Inclusion (Mar 2026): Lessons from a Sep 2025 Retrospective Event Study

HSCI / Hong Kong Connect Inclusion (March 2026): A Preliminary Assessment

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Event-Driven

<ul>
<li>Shanghai Stock Exchange and Shenzhen Stock Exchange confirmed 40 ADDs and 25 DELETEs for Connect implementation on 9 March 2026.</li>
<li>The DELETE trade has worked well, with mean WAI return of -10.0% (21/25 negative); ADD stocks underperformed during WAI at -3.3% mean, consistent with the September 2025 event study.</li>
<li>Selectivity remains critical into implementation: favor narrative-aligned ADDs with moderate pre-event extension, maintain DELETE shorts on high-Connect-holding names, and monitor the three delayed ADDs for secondary entry points.</li>
</ul>


Shanghai Stock Exchange and Shenzhen Stock Exchange confirmed 40 ADDs and 25 DELETEs for Connect implementation on 9 March 2026.
The DELETE trade has worked well, with mean WAI return of -10.0% (21/25 negative); ADD stocks underperformed during WAI at -3.3% mean, consistent with the September 2025 event study.
Selectivity remains critical into implementation: favor narrative-aligned ADDs with moderate pre-event extension, maintain DELETE shorts on high-Connect-holding names, and monitor the three delayed ADDs for secondary entry points.


China Resources Medical Holdings (1515 HK)

HSCI / HK Connect (March 2026): Implementation Today & Positioning

Insilico Medicine

HSCI / HK Connect (March 2026): Implementation Today & Positioning